Protein biomarker and uses thereof
The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.
1. A method of treating a human subject harboring head and neck cancer comprising administering a treatment comprising an anti-HER3 antibody to a human subject diagnosed with head and neck cancer, wherein the head and neck cancer has progressed on at least one prior systemic therapy and a protein level of heregulin (HRG) in a sample of the head and neck cancer obtained from the subject is determined to be higher than 980 pg/mL using an FDA-approved test for detecting HRG at the protein level, and wherein HRG is the only protein for which the protein level is assessed.
2. The method of claim 1 in which the HRG gene expression at a protein level in blood, circulating tumor cells, or a biopsy taken from the subject diagnosed with head and neck cancer.
3. The method of claim 2 in which the biological sample comprises a whole blood or serum sample.
4. The method of claim 1 in which the protein level of HRG in the sample of the head and neck cancer obtained from the subject about 100000 pg/mL.
5. The method of claim 1 , wherein the subject harbors wild-type EGFR.
6. The method of claim 1 , further comprising assessing gene expression at a protein level in the human subject diagnosed with the head and neck cancer, wherein the HRG gene expression at a protein level is assessed using ELISA or immunohistochemistry techniques.
7. The method of claim 1 in which the anti-HER3 antibody is selected from the group consisting of patritumab, duligotumab (MEHD-7945A), seribantumab (MM-121), MM-111, LJM716, RG-7116, tri-specific anti-EGFR/ERBB3 zybody, huHER3-8, and an antigen-binding or fragment of any of these.
8. The method of claim 1 in which the treatment comprises an anti-HER3 antibody in combination with one or more of (i) a HER inhibitor, (ii) a chemotherapy, (iii) radiation and (iv) an other targeted agent.
9. The method of claim 8 , wherein the HER inhibitor is selected from the group consisting of trastuzumab, T-DM1, lapatinib, pertuzumab, cetuximab, panitumumab gefitinib, afatinib, dacomitinib, KD-019 and erlotinib.
10. The method of claim 8 , wherein the chemotherapy is selected from the group consisting of cisplatin, carboplatin, gemcitabine, pemetrexed, irinotecan, 5-fluoruracil, paclitaxel, docetaxel, and capecitabine.
11. The method of claim 8 , wherein the anti-HER3 antibody is administered in combination with (i) cetuximab and (ii) cisplatin or carboplatin.
12. The method of claim 11 , wherein the anti-HER3 antibody is patritumab.